arrow
J

James Logue

university of maryland baltimore
H指数:31
被引数:7,871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responses
2023-12-011
OAAI
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
2023-02-287
OAAI
Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans
2023-01-253
OAAI
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
2022-11-0152
OAAI
Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity

具有广谱抗病毒活性的自组装短免疫刺激性双链体rna

2022-09-0112
OAAI
Defining the risk of SARS-CoV-2 variants on immune protection
Nature
IF48.5
2022-03-310
PRE
Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection
2021-12-068
OAAI
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021-10-18204
OAAI
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
2021-09-210
PREAI
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Fab和Fc在NVX-CoV2373亚单位疫苗与Matrix-M疫苗接种后可最大程度地保护SARS-CoV-2

2021-09-0180
OAAI
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

用于快速鉴定候选抗病毒治疗剂和预防剂的人气道芯片

2021-05-03265
OAAI
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms
2021-03-1052
OAAI
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

SARS-CoV-2刺突糖蛋白候选疫苗在狒狒中的NVX-CoV2373免疫原性及对小鼠的保护作用

2021-01-14338
OAAI
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
2020-12-10870
OAAI